The Recombinant Vaccine against Human Chorionic Gonadotropin goes on Combined Immunogenicity, Safety and Efficacy Clinical Trials

Abstract

A chemically synthesized vaccine inducing antibodies against human chorionic gonadotropin (hCG) was previously developed by et al. [1] which had undergone successfully Phase I and Phase II efficacy Clinical trials in sexually active women showing its ability to prevent pregnancy without derangement of ovulation,hormonal profiles and menstrual regularity (Table 1). It had high efficacy with only one pregnancy occurring in 1224 cycles. It was fully reversible and women desirous of having another child conceived readily on antibodies falling below 20ng/ ml binding capacity [2]. The progeny born to previously immunized women had developmental land marks and cognitive abilities similar to their siblings [3].